Department of Pathology;
Shenzhen Institute of Research and Innovation and Shenzhen Hospital;
The University of Hong Kong;
Hong Kong;
Chongqing International Institute for Immunology;
Chongqing;
China;
Institute of Medical Immunology;
Affiliated Hospital of Jiangsu University;
Zhenjiang;
China;
Department of Rheumatology and Immunology;
The First Affiliated Hospital and School of Medicine;
Henan University of Science and Technology;
Luoyang;
China;
Department of Dermatology;
Second Xiangya Hospital;
Central South University;
Hunan Key Laboratory of Medical Epigenomics;
Changsha;
Hunan;
China;
Department of Rheumatology;
Guangzhou First People’s Hospital;
School of Medicine;
South China University of Technology;
Guangzhou;
China;
Department of Chemical Pathology;
Faculty of Medicine;
Prince of Wales Hospital;
The Chinese University of Hong Kong;
Hong Kong;
China;
Epigenetics and Immune Disease Group;
Josep Carreras Research Institute;
Badalona;
08916 Barcelona;
Spain;
Epigenetics in Inflammatory and Metabolic Diseases Laboratory;
Health Science Center;
East China Normal University;
Shanghai;
China;
Department of Rheumatology;
Huashan Hospital;
Fudan University;
Shanghai;
China;
Centre for Oncology and Immunology;
Hong Kong Science Park;
Hong Kong;
China;
B cells; Epigenetic regulation; Autoimmune disease; Biomarker; Therapy;